CD274 and gastric cancer: Currently, biomarkers such as PD-L1 positivity, microsatellite instability (MSI)/mismatch repair (MMR), EBV, and tumor mutational load (TMB) are used in gastric cancer patients receiving immunotherapy to predict the effectiveness of immunosuppressive drugs (17).